Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 707, Issue 1-2, 2011, Pages 42-52

  Kumar, V Bharath ^a   Yuan, Ta Chun ^a   Liou, Je Wen ^b   Yang, Chih Jen ^c   Sung, Ping Jyun ^a   Weng, Ching Feng ^a  

^a NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antroquinonol; Caspase cleavage; Cdc2 proteins; MiRNA; PARP; PI3K mTOR

Indexed keywords

ANTINEOPLASTIC AGENT; ANTROQUINONOL; CASPASE 3; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 25C; HERBACEOUS AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTRODIA CAMPHORATA; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIALS; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UBIQUINONE;

TAIWANOFUNGUS CAMPHORATUS;

EID: 79251599621     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2010.12.009     Document Type: Article

References (62)

1. Shivapurkar N., Reddy J., Chaudhary P.M., Gazdar A.F. Apoptosis and lung cancer: a review. J. Cell. Biochem. 2003, 88:885-898.
2. Erridge S.C., Moller H., Price A., Brewster D. International comparisons of survival from lung cancer: pitfalls and warnings. Nat. Clin. Pract. Oncol. 2007, 4:570-577.
3. Cordes N., Beinke C., Plasswilm L., Van Beuningen D. Irradiation and various cytotoxic drugs enhance tyrosine phosphorylation and β1-integrin clustering in human A549 lung cancer cells in a substratum-dependent manner in vitro. Strahlenther. Onkol. 2004, 180:157-164.
4. Chen C.Y., Chen C.H., Lo Y.C., Wu B.N., Wang H.M., Lo W.L., Yen C.M., Lin R.J. Anticancer activity of isoobtusilactone A from Cinnamomum kotoense: involvement of apoptosis, cell-cycle dysregulation, mitochondria regulation, and reactive oxygen species. J. Nat. Prod. 2008, 71:933-940.
5. Peters G.J., Smorenburg C.H., Van Groeningen C.J. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J. Chemother. 2004, 16:25-30.
6. Proctor R.N. Tobacco and the global lung cancer epidemic. Nat. Rev. Cancer 2001, 1:82-86.
7. Jemal A., Murray T., Ward E., Samuels E.A., Tiwari R.C., Ghafoor A., Feuer E.J., Thun M.J. Cancer statistics 2005. CA Cancer J. Clin. 2005, 55:10-30.
8. Maziak D.E., Markman B.R., MacKay J.A., Evans W.K., Cancer Care Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group Photodynamic therapy in non-small cell lung cancer: a systematic review. Ann. Thorac. Surg. 2004, 77:1484-1491.
9. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet 2000, 355:479-485.
10. Carney D.N. Lung cancer - time to move on from chemotherapy. New Engl. J. Med. 2002, 2:126-128.
11. Krishnan K., Campbell S., Abdel-Rahman F., Whaley S., Stone W.L. Cancer chemoprevention drug targets. Curr. Drug Targets 2003, 4:1389-4501.
12. Singh R.P., Dhanalakshmi S., Agarwal R. Phytochemicals as cell cycle modulators: a less toxic approach in halting human cancers. Cell Cycle 2002, 1:56-161.
13. Akhtar S., Meeran S.M., Katiyar N., Katiyar S.K. Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting insulin-like growth factor binding protein-3, tumour cell proliferation, and angiogenic factors. Clin. Cancer Res. 2009, 15:821-831.
14. Zang M., Su C.H. Ganoderma comphoratum, a new taxon in genus Ganoderma from Taiwan, China. Acta Bot. Yunnanica 1990, 12:395-396.
15. Wu S.H., Ryvarden L., Chang T.T. Antrodia cinnamomea (niu-chang-chih), new combination of a medicinal fungus in Taiwan. Bot. Bull. Acad. Sin. 1997, 38:273-275.
16. Chen C.C., Shiao Y.J., Lin R.D., Shao Y.Y., Lai M.N., Lin C.C., Ng L.T., Kuo Y.H. Neuroprotective diterpenes from the fruiting body of Antrodia camphorate. J. Nat. Prod. 2006, 69:689-691.
17. Chen K.C., Peng C.C., Peng R.Y., Su C.H., Chiang H.S., Yan J.H., Hsieh-Li H.M. Unique formosan mushroom Antrodia camphorata differentially inhibits androgen-responsive LNCaP and -independent PC-3 prostate cancer cells. Nutr. Cancer 2007, 57:111-121.
18. Peng C.C., Chen K.C., Peng R.Y., Chyau C.C., Su C.H., Hsieh-Li H.M. Antrodia camphorata extract induces replicative senescence in superficial TCC, and inhibits the absolute migration capability in invasive bladder carcinoma cells. J. Ethnopharmacol. 2007, 109:93-103.
19. Yang H.L., Chen C.S., Chang W.H., Lu F.J., Lai Y.C., Chen C.C., Hseu T.H., Kuo C.T., Hseu Y.C. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorate. Cancer Lett. 2006, 231:215-227.
20. Wu H., Pan C.L., Yao Y.C., Chang S.S., Li S.L., Wu T.F. Proteomic analysis of the effect of Antrodia camphorata extract on human lung cancer A549 cell. Proteomics 2006, 6:826-835.
21. Chan Y.Y., Chang C.S., Chien L.H., Wu T.F. Apoptotic effects of a high performance liquid chromatography (HPLC) fraction of Antrodia camphorata mycelia are mediated by down-regulation of the expressions of four tumour-related genes in human non-small cell lung carcinoma A549 cell. J. Ethnopharmacol. 2010, 127:652-661.
22. Lee T.H., Lee C.K., Tsou W.L., Liu S.Y., Kuo M.T., Wen W.C. A new cytotoxic agent from solid-state fermented mycelium of Antrodia camphorata. Planta Med. 2007, 73:1412-1415.
23. Liu D.Z., Liang H.J., Chen C.H., Sub C.H., Lee T.H., Huang C.T., How W.C., Lin S.Y., Zhong W.B., Lin P.J., Hung L.F., Liang Y.C. Comparative anti-inflammatory characterization of wild fruiting body, liquid-state fermentation, and solid-state culture of Taiwanofungus camphoratus in microglia and the mechanism of its action. J. Ethnopharmacol. 2007, 113:45-53.
24. Chiang P.C., Lin S.C., Pan S.L., Kuo C.H., Tsai I.L., Kuo M.T., Wen W.C., Chen P., Guh J.H. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem. Pharmacol. 2010, 79:162-171.
25. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
26. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8:179-183.
27. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev. 2008, 34:378-390.
28. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
29. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81:727-736.
30. Franke T.F., Cantley L.C. Apoptosis. A bad kinase makes good. Nature 1997, 390:116-117.
31. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 1998, 273:19929-19932.
32. Blower P.E., Chung J.H., Verducci J.S., Lin S., Park J.K., Dai Z., Liu C.G., Schmittgen T.D., Reinhold W.C., Croce C.M., Weinstein J.N., Sadee W. MicroRNAs modulate the chemosensitivity of tumour cells. Mol. Cancer Ther. 2008, 7:1-9.
33. Croce C.M., Calin G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122:6-7.
34. Gregory R.I, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005, 65:3509-3512.
35. Zhao J., Li Q.Q., Zou B., Wang G., Li X., Kim J.E., Cuff C.F., Huang L., Reed E., Gardner K. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Int. J. Oncol. 2007, 31:241-252.
36. Impens F., Van Damme P., Demol H., Van Damme J., Vandekerckhove J., Gevaert K. Mechanistic insight into taxol-induced cell death. Oncogene 2008, 33:4580-4591.
37. Tang X., Downes C.P., Whetton A.D., Owen-Lynch P.J. Role of phosphatidylinositol 3-kinase and specific protein kinase B isoforms in the suppression of apoptosis mediated by the Abelson protein-tyrosine kinase. J. Biol. Chem. 2000, 275:13142-13148.
38. Zhang F., Zhang T., Jiang T., Zhang R., Teng Z.H., Li C., Gu Z.P., Mei Q. Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumour cells by repressing PI3K/Akt pathway. Cancer Lett. 2009, 286:232-239.
39. Giuseppe G. Targeted therapy in non-small cell lung cancer. Lung Cancer 2002, 38:29-32.
40. Shukla S., Gupta S. Molecular mechanisms for apigenin induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol. Carcinog. 2004, 39:114-126.
41. Jacks T., Weinberg R.A. Cell-cycle control and its watchman. Nature 1996, 381:643-644.
42. O'Connor P.M., Ferris D.K., Pagano M., Draetta G., Pines J., Hunter T., Longo D.L., Kohn K.W. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2, and cyclin B1/cdc-2 kinase complexes differently. J. Biol. Chem. 1993, 268:8298-8308.
43. Lew D.J., Kornbluth S. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Cell. Biol. 1996, 8:795-804.
44. Yang C.J., Wang C.S., Hung J.Y., Huang H.W., Chia Y.C., Wang P.H., Weng C.F., Huang M.S. Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumour growth in an animal model. Lung Cancer 2009, 66:162-168.
45. Shibuya E.K. G2 cell cycle arrest-a direct link between PKA and Cdc25C. Cell Cycle 2003, 2:39-41.
46. Gao C.F., Xie Q., Su Y.L., Koeman J., Khoo S.K., Gustafson M., Knudsen B.S., Hay R., Shinomiya N., Woude G.F.V. Proliferation and invasion: plasticity in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 30:10528-10533.
47. Wang J., Wan Z., Liu W., Li L., Ren L., Wang X., Sun P., Ren L., Zhao H., Tu Q., Zhang Z., Song N., Zhang L. Atomic force microscope study of tumour cell membranes following treatment with anti-cancer drugs. Biosens. Bioelectron. 2009, 4:721-727.
48. Antignani A., Youle R.J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane. Curr. Opin. Cell Biol. 2006, 18:685-689.
49. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
50. Jiang C., Yang Y.F., Cheng S.H. Fas ligand gene therapy for vascular intimal hyperplasia. Curr. Gene Ther. 2004, 4:33-39.
51. Cai X., Gao S., Cai J., Wu Y., Deng H. Artesunate induced morphological and mechanical changes of Jurkat cell studied by AFM. Scanning 2009, 31:83-89.
52. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., Earnshaw W.C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371:346-347.
53. Adhami V.M., Siddiqui I.A., Ahmad N., Gupta S., Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signalling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004, 64:8715-8722.
54. Janmaat M.L., Kruyt F.A.E., Rodriguez J.A., Giaccone G. Response to epidermal growth factor receptor inhibitors in non small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 2003, 9:2316-2326.
55. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
56. Chen X, Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Zhang Y., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Wang J., Zen K., Zhang J., Zhang C.Y. Characterization of miRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
57. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., Banham A.H., Pezzella F., Boultwood J., Wainscoat J.S., Hatton C.S., Harris A.L. Detection of elevated levels of tumour associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
58. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
59. Lee E.M., Shin S., Cha H.J., Yoon Y., Bae S., Jung J.H., Lee S.M., Lee S.J., Park I.C., Jin Y.W., An S. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int. J. Mol. Med. 2009, 24:45-50.
60. Bandi N., Zbinden S., Gugger M., Arnold M., Kocher V., Hasan L., Kappeler A., Brunner T., Vassella E. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009, 13:5553-5559.
61. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:13944-13949.
62. * microRNA functions as a potential tumour suppressor by targeting on K-Ras. Carcinogenesis 2009, 6:953-959.